drugset
drugset / Trial / NCT01769898

The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis

NCT01769898 ↗

Phase 4 Completed 50 enrolled The First Affiliated Hospital of Guangzhou Medical University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to examine the efficacy and safety of 24 weeks treatment with theophylline plus low-dose formoterol-budesonide in subjects with bronchiectasis.

Timeline

Start
2013-07
Primary completion
2014-09
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Theophylline Small molecule — Oral
Background Symbicort Unknown 4.5 ug Inhaled
Background Symbicort Unknown 160 ug Inhaled

Indications

bronchiectasis